Overview of Inflammatory Breast Cancer: Updates
- 1st Edition, Volume 384 - April 18, 2024
- Editors: Marwa Manai, Massimo Cristofanilli, Hamouda Boussen
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 4 8 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 4 9 - 7
International Review of Cell and Molecular Biology, Volume 381 highlights new advances in the field, with this new volume presenting interesting topic on Overview of Inflammatory… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteInternational Review of Cell and Molecular Biology, Volume 381 highlights new advances in the field, with this new volume presenting interesting topic on Overview of Inflammatory Breast Cancer: Updates.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in International Review of Cell and Molecular Biology
- Updated release includes the latest information on Overview of Inflammatory Breast Cancer and Updates
Academic, government and industrial sectors
1. The last epidemiological and clinicopathological aspects of inflammatory breast cancer/or/Updated knowledge about the role of genetic and epidemiology in inflammatory breast cancer
2. Inflammatory breast cancer: updates on surgical management
3. Updates on oncogenomic profiling of inflammatory breast cancer
4. Inflammatory breast cancer biomarkers and biology
5. Patient advocacy for inflammatory breast cancer
6. Radiation on inflammatory breast cancer: updates
7. IBC and the new potential targets: updates/review
8. The role of the tumor microenvironment on inflammatory breast cancer: updates
- No. of pages: 277
- Language: English
- Edition: 1
- Volume: 384
- Published: April 18, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443133480
- eBook ISBN: 9780443133497
MM
Marwa Manai
A scientist-researcher working on Inflammatory Breast Cancer (IBC)
Affiliations and expertise
Weill Cornell Medicine, Department of Medicine, Division of hematology-oncology, NY, USAMC
Massimo Cristofanilli
Massimo Cristofanilli, MD, is an accomplished board-certified medical oncologist with more than two decades of experience as physician, investigator, researcher and leader. He has demonstrated original and innovative vision in the field of molecular diagnostics, liquid biopsy, translational research and drug development. Additionally, Dr. Cristofanilli has an extensive background in clinical trial design and is a key thought leader in the field of metastatic and locally advanced breast cancer. At Weill Cornell Medicine and NewYork-Presbyterian, Dr. Cristofanilli serves as the Director of Breast Medical Oncology, the Associate Director of Precision Oncology at the Meyer Cancer Center (MCC), and the co-leader of the MCC Breast Cancer Disease Management Team, as well as the Scientific Director of the Englander Institute of Precision Medicine (EIPM). Dr. Cristofanilli received his medical degree from the University “La Sapienza” in Rome with Honors where he subsequently completed his fellowship in medical oncology. He completed an Internal Medicine residency at Cabrini Medical Center in New York and a medical oncology fellowship at The University of Texas MD Anderson Cancer Center, where he also served as Faculty in the Department of Breast Medical Oncology for more than a decade.Dr. Cristofanilli has held several leadership positions over the years, including Chairman of Medical Oncology and Associate Director of Clinical Research at the Fox Chase Cancer Center and Associate Director of Translational Research at Thomas Jefferson University. From 2015-2021, Dr. Cristofanilli was Professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago where he also served as the Director of the Breast Disease Team, Director of the Robert Lurie Cancer Center OncoSET Precision Medicine Program, and Associate Director of Clinical Research. In addition to his clinical expertise, Dr. Cristofanilli’s research focuses on biomarkers of endocrine resistance in breast cancer, liquid biopsies and novel drug development. His research in the areas of novel drug development, circulating tumor cells (CTCs) and ctDNA have led to improved treatments for breast cancer. Dr. Cristofanilli is an internationally recognized expert in the research and treatment of Inflammatory Breast Cancer (IBC), the most aggressive and deadly form of breast cancer. He is the founder and President of the IBC International Consortium (IBC-IC). Additionally, Dr. Cristofanilli is globally recognized for his contributions on the detection of micrometastatic disease in breast cancer and a key opinion leader in drug development in hormone-receptor positive metastatic breast cancer. He has co-authored more than 400 peer-reviewed manuscripts.
Affiliations and expertise
Department of Medicine, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10021HB
Hamouda Boussen
Dr. Boussen is a physician and researcher working on several areas of medical oncology. He conducted several clinical trials on breast cancer and inflammatory breast cancer and was one of lead researchers on this disease in Tunisia.
Affiliations and expertise
Medical oncology service , Hospital of Ariana, Ariana, TunisiaRead Overview of Inflammatory Breast Cancer: Updates on ScienceDirect